The single-pill combination (SPC) comprising nebivolol (5mg), a vasodilatory β 1 -selective antagonist/β 3 -agonist, and valsartan (80mg), a renin-angiotensinaldosterone system inhibitor, is the only Food and Drug Administration-approved β-blocker/renin-angiotensin-aldosterone system inhibitor SPC for hypertension. 
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| INTRODUCTION
In the United States, hypertension continues to be one of the most widespread,modifiableconditionsandremainsaleadingriskfactorfor cardiovasculardisease. and/or tolerability can be achieved through additive drug effects. 4, 5 TreatmentcombinationsareadditivewhentheyconfergreaterBPreductionsthaneithermonotherapyalone. 5 Additivityiscompletewhen theBP-loweringeffectofthecombinationisequaltothesumofthe effectsofthemonotherapies. 4 In previous trials, combinations consisting of a β-blocker and a renin-angiotensin-aldosteronesystem(RAAS)inhibitor,suchasanangiotensinreceptorblocker(ARB)oranangiotensin-convertingenzyme inhibitor(ACEI),havedemonstratedalackofadditivitycomparedwith other antihypertensive combinations. 5, 6 For example, results from a study in which the β 1 -selective, nonvasodilatory β-blocker atenolol was combined with enalapril 7 and, more recently, the primary analysisoftheCOSMOS(CoregandLisinoprilCombinationTherapyin HypertensiveSubjects)studyexaminingthenon-β 1 -selective,vasodilatoryβ-blockercarvedilolpluslisinopril, 8 failedtoshowadditivedrug effects. These combinations may have lacked additive BP-lowering effectsasaresultofsimilarmechanismsofactionofthecomponent monotherapies(ie,RAASinhibition). [9] [10] [11] Nebivololisaneffectiveandwell-toleratedβ 1 -selectiveadrenergic blockerwith β 3 -agonisticvasodilatory effects,which differentiates it fromotherβ-blockerssuchasmetoprololandatenolol(nonvasodilatory, β 1 -selective) and carvedilol (vasodilatory, non-β 1 -selective). 12, 13 Nebivolol also has a better tolerability profile than other β-blockers (2.8% adverse event-related discontinuations for nebivolol vs 2.2% placebo 14 )andminimalmetaboliceffects. 15, 16 Valsartan,anARBthat selectivelyblockstheangiotensinIItype1receptorandreducesox-idativestress,isalsoeffectiveinreducingBPwithagoodsafetyand tolerabilityprofile. [17] [18] [19] Evidencethataβ-blocker/RAASinhibitorcombination-specificallycombinationswithnebivolol-maybean effective 
| METHODS

| Data
BPdataforfournebivolol/valsartanSPCs(nebivolol5mg/valsartan 80mg,5/160mg,10/160mg,and10/320mg)wereobtainedfrom a previously reported phase 3, randomized, double-blind, placebocontrolledtrial(NAC-MD-01;NCT01508026). 21 FiveFoodandDrug Administration-approved, non-β-blocker/RAAS inhibitor SPCs were identified as comparators: aliskiren/hydrochlorothiazide (150/12.5 mg, 150/25 mg, 300/12.5 mg, 300/25 mg) 22 ; aliskiren/amlodipine (150/5 mg, 150/10 mg, 300/5 mg, 300/10mg) 23, 24 ; aliskiren/valsartan (150/160 mg, 300/320 mg) 25 ; valsartan/amlodipine (160/5 mg, 160/10 mg, 320/5 mg, 320/10 mg) 26 ; and telmisartan/amlodipine (40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg). 27 BP data for the comparators were collected from pivotal, randomized, double-blind, placebo-controlledefficacyandsafetytrialsavailableontheDrugs@ FDAwebsite. 28 Alltrialsoccurredover8weeksandincludedasingle-blindrun-in period ranging from 2 to 6weeks. At least one active treatment was uptitrated in all trials: amlodipine doses were doubled after 1 to 2weeks, 23, 24, 26 hydrochlorothiazide doses were doubled after 1 week, 22 anddosesofallactivetreatmentsweredoubledinthealiskiren/valsartanandnebivolol/valsartantrialsafter4weeks.
21,25
| Trial populations
The trial populations for these analyses were generally similar and 
| RESULTS
The additivity ratio scores were similar for the nebivolol/valsartan SPCsandforthemajorityofthenon-β-blocker/RAASinhibitorSPCs, with most scores below 1, indicating partial additivity (Figure1A,B) . 
12,32
Thus,the positiveresultsofthecurrentanalysismaybeexplainedbythemultiplemechanismsofactionfornebivololsuchasvasodilation,decreased peripheralresistance,decreasedmyocardialcontractility,andsuppression of renin activity. 13, 33 In addition, nebivolol is highly selective for theβ 1 -receptors(ie,cardioselective),producesendothelium-dependent vasodilation via nitric oxide, and is also a β 3 -receptor agonist. 
| STUDY LIMITATIONS
| CONCLUSIONS
Theadditivityscoresofnebivolol/valsartanSPCsandselectednon-β-blocker/RAAS inhibitor SPCs are comparable, with both componentscontributingtotheBP-loweringeffect. Neutelfunctionedasaprincipalinvestigatorinthisstudy.
ACKNOWLEDGMENTS
ORCID
Jack Ishak
http://orcid.org/0000-0002-9311-2399
